LEVODOPA/CARBIDOPA GPPL 250/25 levodopa 250 mg and carbidopa (as monohydrate) 25 mg tablet blister pack

Land: Ástralía

Tungumál: enska

Heimild: Department of Health (Therapeutic Goods Administration)

Virkt innihaldsefni:

carbidopa monohydrate, Quantity: 27 mg (Equivalent: carbidopa, Qty 25 mg); levodopa, Quantity: 250 mg

Fáanlegur frá:

Arrotex Pharmaceuticals Pty Ltd

Lyfjaform:

Tablet, uncoated

Samsetning:

Excipient Ingredients: magnesium stearate; crospovidone; microcrystalline cellulose; pregelatinised maize starch; indigo carmine aluminium lake

Stjórnsýsluleið:

Oral

Einingar í pakka:

20 tablets, 10 tablets, 100 tablets

Gerð lyfseðils:

(S4) Prescription Only Medicine

Ábendingar:

LEVODOPA/CARBIDOPA GPPL is indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. LEVODOPA/CARBIDOPA GPPL frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.

Vörulýsing:

Visual Identification: Round, light blue uncoated tablets with 'C' on one side and '20' on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Leyfisstaða:

Registered

Leyfisdagur:

2018-01-11